0915FD2C-0C30-4437-83BA-DFBDF3CDBC61
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 17.871222076215506
- age_years
- 47
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- NOTCH_SIGNALING+0.554
- WNT_BETA_CATENIN_SIGNALING+0.498
- MYC_TARGETS_V2+0.450
- DNA_REPAIR+0.408
- MYC_TARGETS_V1+0.380
- TGF_BETA_SIGNALING+0.347
- MITOTIC_SPINDLE+0.273
- UNFOLDED_PROTEIN_RESPONSE+0.273
- G2M_CHECKPOINT+0.259
- ADIPOGENESIS+0.252
Top 10 suppressed
- KRAS_SIGNALING_DN-0.369
- SPERMATOGENESIS-0.321
- PANCREAS_BETA_CELLS-0.299
- INFLAMMATORY_RESPONSE-0.176
- TNFA_SIGNALING_VIA_NFKB-0.141
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.131
- KRAS_SIGNALING_UP-0.126
- MYOGENESIS-0.089
- HYPOXIA-0.081
- UV_RESPONSE_DN-0.065
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 7ACD648E-76FD-4C83-86AA-51F581A0B09C | — | — | 0.882 |
| 2 | 17C2A071-0813-4992-96D8-5C432D6EC9E6 | — | — | 0.879 |
| 3 | 635170D3-D669-4165-B69C-9C9A246BFF11 | — | — | 0.865 |
| 4 | E81FA8B7-3FFE-4F73-94AF-0B5257D7F81A | — | — | 0.861 |
| 5 | 53BA607F-7939-40D9-BEFA-DC4ABDC7630B | — | — | 0.857 |
| 6 | 51708DA2-649D-4817-BB26-7FD153C65965 | — | — | 0.854 |
| 7 | B13E4D9F-672E-4A9A-8745-0AE5308678C1 | — | — | 0.851 |
| 8 | 1F4B7E2E-E242-410A-AE78-8FC412D3C0A9 | — | — | 0.847 |
| 9 | 9FCC850A-554E-4E56-95BA-F7F5CF0D5012 | — | — | 0.846 |
| 10 | 8EB94F84-902E-4547-BF1D-5171931EDEDD | — | — | 0.846 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| NOTCH_SIGNALING | 0.554 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.498 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.450 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.408 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.380 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.347 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.273 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.273 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.259 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.252 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.208 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.196 | Inavolisib | — uncovered |
| PEROXISOME | 0.188 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.171 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.154 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.147 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.133 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.132 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.130 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.123 | Inavolisib | — uncovered |